About Index Trending news
Analyze
Pricing
AbbVie

AbbVie

AbbVie

AbbVie's official global Twitter feed featuring news and updates managed by our global newsroom. Review our Twitter guidelines here on our site

Elsewhere

Alexa global traffic share

Twitter followers

Employees

Team size

10000+
Locations
HQ
Xconomy

More Job Cuts at Infinity As AbbVie Sends Back Blood Cancer Drug

Health
The Motley Fool

Better Buy: Merck & Co. Inc. vs. AbbVie

Stock markets Health
The Motley Fool

Better Buy: AbbVie Inc. vs. Johnson & Johnson

The Motley Fool

AbbVie's Rova-T Update at ASCO: Good or Bad?

Health
The Motley Fool

3 Reasons to Buy AbbVie Inc.

The Motley Fool

Is AbbVie's Stock Too Risky?

The Motley Fool

3 Reasons AbbVie's and Biogen's Latest MS Drug Might Flop

The Motley Fool

A Heavy Hitter Just Stepped Up to the Cystic Fibrosis Plate

The Motley Fool

Why June Could Be a Big Month for AbbVie Investors

via Bloomberg , TechCrunch

Stemcentrx Sale to Return a Record $1.7 Billion for VC Firm Founders Fund

Funding Health
The Motley Fool , Silicon Beat

Sanofi's Bid for Medivation Is Too Low

$5,800,000,000
TechCrunch , Xconomy , Business Insider , +1

AbbVie acquiring cancer drug startup StemcenTrx for $5.8 billion

Health Funding Strategy
The Motley Fool

Better Buy: Pfizer Inc. vs. AbbVie

Stock markets Health
The Motley Fool

AbbVie's Venclexta Notches FDA Win, But Investors Might Want To Temper Enthusiasm

The Motley Fool

Better Buy: AbbVie vs. Johnson & Johnson

The Motley Fool

AstraZeneca or AbbVie: Which Is Better for Dividend Growth Investors?

The Motley Fool

AbbVie Inc.'s Big Win Over Gilead Sciences Wasn't in Hepatitis C

The Motley Fool

Better Buy: AbbVie Inc. vs. Eli Lilly

Health Earnings
The Motley Fool

Instant Analysis: Regeneron Pharmaceuticals and Sanofi's Experimental Drug Bests an AbbVie Blockbuster

The Motley Fool

Is This the Company Gilead Sciences Should Fear Most? (Hint: It's Not Merck or AbbVie)